Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (1296/18)
18/04/2018
Indication
Monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
50mg powder for concentrate for solution for infusion and 25mg/mL concentrate for solution for infusion
Comments
April 2018 - Not routinely available as local experts do not wish to add the medicine to the formulary at this time.